Related Experiment Videos
Injection of T-cell receptor peptide reduces immunosenescence in aged C57BL/6 mice
Abstract:
Previous studies established that retrovirally infected young mice produced large amounts of autoantibodies to certain T-cell receptor (TCR) peptides whose administration diminished retrovirus-induced immune abnormalities. C57BL/6 young (4 weeks) and old (16 months) female mice were injected with these same synthetic human TCR V beta 8.1 or 5.2 peptides. Administration of these autoantigenic peptides to old mice prevent immunosenescence, such as age-related reduction in splenocyte proliferation and interleukin-2 (IL-2) secretion. TCR V beta peptide injection into young mice had no effect on T- or B-cell mitogenesis and IL-4 production while modifying tumour necrosis factor-alpha (TNF-alpha), IL-6, and interferon-gamma (IFN-gamma) secreted by mitogen-stimulated spleen cells. TCR V beta injection also retarded the excessive production of IL-4, IL-6 and TNF-alpha induced by ageing. These data suggest that immune dysfunction and abnormal cytokine production, induced by the ageing process, were largely prevented by injection of selected TCR V beta CDR1 peptides.
Insights
Injecting T-cell receptor (TCR) V beta peptides into old mice prevented immunosenescence, an age-related decline in immune function. This peptide therapy also corrected abnormal cytokine production in both young and old mice.
Area of Science:
- Immunology
- Gerontology
- Molecular Biology
Background:
- Previous research indicated that T-cell receptor (TCR) peptides could mitigate retrovirus-induced immune issues in young mice.
- Immunosenescence, characterized by reduced immune cell function and altered cytokine profiles, is a hallmark of aging.
Purpose of the Study:
- To investigate the impact of synthetic human TCR V beta 8.1 or 5.2 peptide administration on immune function in young and old C57BL/6 mice.
- To determine if TCR V beta peptide injection could prevent age-related immune decline and correct aberrant cytokine production.
Main Methods:
- Young (4 weeks) and old (16 months) female C57BL/6 mice were injected with synthetic human TCR V beta 8.1 or 5.2 peptides.
- Splenocyte proliferation, interleukin-2 (IL-2) secretion, and production of cytokines including IL-4, IL-6, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) were assessed.
Main Results:
- In old mice, TCR V beta peptide administration prevented age-related decreases in splenocyte proliferation and IL-2 secretion.
- In young mice, peptide injection did not affect T- or B-cell mitogenesis or IL-4 production but modulated TNF-alpha, IL-6, and IFN-gamma levels.
- TCR V beta peptide administration counteracted the excessive production of IL-4, IL-6, and TNF-alpha observed in aged mice.
Conclusions:
- Administration of specific T-cell receptor (TCR) V beta CDR1 peptides can prevent immunosenescence and correct age-associated immune dysfunction.
- TCR V beta peptide therapy holds potential for mitigating age-related immune decline and restoring balanced cytokine production.